BR0017332A - Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico - Google Patents

Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico

Info

Publication number
BR0017332A
BR0017332A BR0017332-0A BR0017332A BR0017332A BR 0017332 A BR0017332 A BR 0017332A BR 0017332 A BR0017332 A BR 0017332A BR 0017332 A BR0017332 A BR 0017332A
Authority
BR
Brazil
Prior art keywords
hepatitis
virus
peptide
induction
nucleic acid
Prior art date
Application number
BR0017332-0A
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Maria A Vitiello
Brian D Livingston
Esteban Celis
Ralph T Kubo
Howard M Grey
Robert W Chesnut
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of BR0017332A publication Critical patent/BR0017332A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"INDUçãO DE RESPOSTAS IMUNES CELULARES AO VìRUS DA HEPATITE B USANDO COMPOSIçõES DE PEPTìDEO E áCIDO NUCLéICO". Esta invenção utiliza nosso conhecimento dos mecanismos pelos quais o antígeno é reconhecido pelas células T para desenvolver vacinas a base de epítopo direcionadas ao HBV. Mais especificamente, este pedido apresenta nossa descoberta das composições farmacêuticas e processos de uso na prevenção e tratamento de infecção por HBV.
BR0017332-0A 2000-09-08 2000-09-08 Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico BR0017332A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/024802 WO2002019986A1 (en) 2000-09-08 2000-09-08 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions

Publications (1)

Publication Number Publication Date
BR0017332A true BR0017332A (pt) 2003-10-07

Family

ID=21741762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017332-0A BR0017332A (pt) 2000-09-08 2000-09-08 Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico

Country Status (10)

Country Link
US (1) US20070059799A1 (pt)
EP (1) EP1322288A4 (pt)
JP (1) JP2004508320A (pt)
KR (1) KR20030055261A (pt)
CN (1) CN1454082A (pt)
AU (1) AU7828100A (pt)
BR (1) BR0017332A (pt)
CA (1) CA2422506A1 (pt)
MX (1) MXPA03002035A (pt)
WO (1) WO2002019986A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AU2002322009A1 (en) * 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
KR20050083719A (ko) * 2002-10-03 2005-08-26 에피뮨 인코포레이티드 최적화된 멀티-에피토프 구성체 및 이의 용도
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
AU2005319578A1 (en) 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
WO2007110098A1 (en) * 2006-03-29 2007-10-04 Institut National De La Sante Et De La Recherche Medicale HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV
KR20090039707A (ko) 2006-06-30 2009-04-22 킴 래버러터리즈, 아이엔씨. 노로바이러스용 항체
WO2008144675A1 (en) 2007-05-17 2008-11-27 Neopro Labs, Llc Crystalline and amorphous forms of peptide
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
NZ586074A (en) * 2010-06-10 2013-07-26 Auckland Uniservices Ltd LCLRP peptides, constructs and uses thereof
CN101979405A (zh) * 2010-08-27 2011-02-23 中国人民解放军第三军医大学 乙肝病毒核心抗原的免疫显性hla-a3超型限制性ctl表位及其鉴定方法和应用
CN102796172B (zh) * 2011-05-23 2015-03-25 中国科学院微生物研究所 一组乙型肝炎病毒特异型的hla_a33限制性表位肽及其应用
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10155036B2 (en) 2014-02-28 2018-12-18 Emergex Vaccines Holding Ltd. MHC class I associated peptides for prevention and treatment of hepatitis B virus infection
EP3225628A4 (en) * 2014-11-28 2018-03-14 Celltrion Inc. Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus
CN105727280B (zh) * 2016-03-25 2021-01-19 汪和睦 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
CN105727279B (zh) * 2016-03-25 2019-01-15 汪和睦 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107022006A (zh) * 2017-03-28 2017-08-08 东南大学 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽序列
CN110172080B (zh) * 2019-05-16 2022-05-24 南京大户生物科技有限公司 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
WO2021110919A1 (en) 2019-12-07 2021-06-10 Isa Pharmaceuticals Treatment of diseases related to hepatitis b virus
CN112725531B (zh) * 2021-01-20 2023-03-21 贵州中医药大学第二附属医院 一种mcda结合生物传感器的乙肝病毒快速检测***

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
DK0637335T3 (da) * 1992-04-21 2007-11-26 Pasteur Institut Rekombinante mutanter til induktion af specifikke immunreaktioner
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
AU4078599A (en) * 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same

Also Published As

Publication number Publication date
WO2002019986A1 (en) 2002-03-14
AU7828100A (en) 2002-03-22
JP2004508320A (ja) 2004-03-18
US20070059799A1 (en) 2007-03-15
CA2422506A1 (en) 2002-03-14
WO2002019986A9 (en) 2002-08-01
EP1322288A4 (en) 2005-02-23
MXPA03002035A (es) 2004-12-13
EP1322288A1 (en) 2003-07-02
KR20030055261A (ko) 2003-07-02
CN1454082A (zh) 2003-11-05

Similar Documents

Publication Publication Date Title
BR0017332A (pt) Indução de respostas imunes celulares ao vìrus da hepatite b usando composições de peptìdeo e ácido nucléico
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
BR9908599A (pt) Composições combinadas de vacina
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
DE895535T1 (de) Grippevirus, repliziert in säugerzellkultur, und impfstoffherstellung
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE387214T1 (de) Impfstoff gegen bakterielle antigene
BR0014282A (pt) Vacinas
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
Vidor et al. Clinical development of a new inactivated hepatitis A vaccine
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
DE69943042D1 (de) Herstellungsverfahren von dispergiermittel enthaltenden konzentrate mit hohem molekulargewicht
WO2002035981A3 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
FI923020A (fi) Inte a inte b-sekvenser.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
DE69937258D1 (de) Genetische impstoffe mit adjuvans
ES2095258T3 (es) Nuevo virus de la enfermedad de la bolsa infecciosa.
DK1180041T3 (da) Vaccine med ISA-virus
PT1149901E (pt) Mutantes de pestivirus e vacinas contendo os mesmos
RU2001127052A (ru) Штамм вируса Эбола "Заир Ч-15" для проведения модельных экспериментов и приготовления диагностических и вакцинных препаратов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/005 (2006.01), A61K 38/00 (2006.01), A61K